




Discovery of new vascular disrupting agents based on evolutionarily conserved drug action, pesticide resistance mutations, and humanized yeast

Riddhiman K. Garge ^{1,†}, Hye Ji Cha,^{1,2,†} Chanjae Lee,¹ Jimmy D. Gollihar,^{1,3} Aashiq H. Kachroo ⁴, John B. Wallingford,^{1,*} and Edward M. Marcotte ^{1,*}

¹Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA

²Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA

³US Army Research Laboratory—South, Austin, TX 78758, USA

⁴The Department of Biology, Centre for Applied Synthetic Biology, Concordia University, Montreal, QC H4B 1R6, Canada

*Corresponding authors: Email: wallingford@austin.utexas.edu (J.B.W.); marcotte@utexas.edu (E.M.M.)

[†]These authors contributed equally to this work.

Abstract

Thiabendazole (TBZ) is an FDA-approved benzimidazole widely used for its antifungal and antihelminthic properties. We showed previously that TBZ is also a potent vascular disrupting agent and inhibits angiogenesis at the tissue level by dissociating vascular endothelial cells in newly formed blood vessels. Here, we uncover TBZ's molecular target and mechanism of action. Using human cell culture, molecular modeling, and humanized yeast, we find that TBZ selectively targets only 1 of 9 human β -tubulin isotypes (TUBB8) to specifically disrupt endothelial cell microtubules. By leveraging epidemiological pesticide resistance data and mining chemical features of commercially used benzimidazoles, we discover that a broader class of benzimidazole compounds, in extensive use for 50 years, also potentially disrupt immature blood vessels and inhibit angiogenesis. Thus, besides identifying the molecular mechanism of benzimidazole-mediated vascular disruption, this study presents evidence relevant to the widespread use of these compounds while offering potential new clinical applications.

Keywords: systems biology; evolution; humanized yeast; angiogenesis; vascular disrupting agents; phenologs; epidemiology

Introduction

The vascular system is built by the combination of *de novo* formation of blood vessels by vasculogenesis and the sprouting of new vessels from existing vessels via angiogenesis (Carmeliet 2005; Herbert and Stainier 2011). Imbalances in angiogenesis underlie a variety of physiological and pathological defects, including ischemic, inflammatory, and immune disorders (Carmeliet 2005; Folkman 2007; Kerbel 2008). Indeed, angiogenesis is central to tumor malignancy and cancer progression, as new blood vessels must be established to supply oxygen and nutrients to the growing tumor. Accordingly, inhibition of angiogenesis is now a well-recognized therapeutic avenue (Folkman 2004, 2007; Carmeliet 2005; Kerbel 2008; Herbert and Stainier 2011). Defined angiogenesis inhibitors such as Avastin (FDA approved since 2004) are now in wide use in the clinic and, over the past 30 years, several dozen drugs have been approved or entered clinical trials as angiogenesis inhibitors (O'Reilly et al. 1994, 1997; Folkman 2004; Nyberg et al. 2005; El-Kenawi and El-Remessy 2013).

In recent years, a new class of anti-vascular drugs, termed vascular disrupting agents (VDAs), have gained attention as potential alternative therapeutics operating by distinct mechanisms (Hinnen and Eskens 2007; Lippert 2007; Heath and Bicknell

2009; Mason et al. 2011). Unlike angiogenesis inhibitors which selectively prevent the formation of new blood vessels, VDAs function by dismantling existing vasculature, making them potentially effective for therapies beyond cancer, for example in the treatment or control of macular degeneration and diabetic retinopathies (Ibrahim et al. 2013; Nowak-Sliwinska et al. 2013). While several VDAs have shown therapeutic potential, none have yet been approved, with several candidates still in clinical trials (Tozer et al. 2005; Cai 2007; Hinnen and Eskens 2007).

Given the lengthy approval process, the failure of many drugs to succeed in clinical trials, and the high costs involved with developing new compounds, drug repurposing offers an attractive alternative for developing new therapies more quickly. We recently developed strategies to exploit data from diverse model organisms to identify both deeply conserved genetic networks as well as small molecules that may manipulate them (McGary et al. 2010; Cha et al. 2012; Woods et al. 2013). This effort identified thiabendazole (TBZ) as both a novel angiogenesis inhibitor and VDA (Cha et al. 2012).

TBZ is one of a large class of biologically active benzimidazole compounds that are widely used commercially or clinically, with applications ranging from photographic emulsions and circuit

board manufacturing to serving as one of the most common heterocyclic ring systems used for small molecule drugs (Taylor et al. 2014). The FDA approved TBZ in 1967 for human use for treating systemic fungal and helminthic infections, but it is more widely used in veterinary settings and agricultural pesticides and preservatives. However, we found that TBZ also possesses potent vascular disrupting ability, demonstrated *in vitro* in human cell culture and *in vivo* in mice and frogs, including for retarding tumor growth and reducing intratumoral vessel density in preclinical murine xenograft models (Cha et al. 2012).

Several other VDAs have been reported to collapse the vasculature by inhibiting microtubule polymerization dynamics via binding β -tubulin (Tozer et al. 2005; Hinnen and Eskens 2007). Indeed, though the basis for TBZ's vascular disrupting action is unknown, it is proposed that TBZ's fungicidal action is mediated via disrupting fungal microtubule assembly and dynamics (Davidse and Flach 1978; Skuce et al. 2010). In particular, mutations in β -tubulin have been frequently found to confer resistance to TBZ in parasitic/invasive fungal and nematode species (Davidse and Flach 1978; Driscoll et al. 1989; Lubega and Prichard 1990; Lacey and Gill 1994; Skuce et al. 2010; Aguayo-Ortiz et al. 2013b; Taylor et al. 2014; Hahnel et al. 2018; Vela-Corcia et al. 2018).

However, in contrast to the situation in yeast, TBZ does not generally disrupt cell growth in vertebrate cells, even in human umbilical vein endothelial (HUVEC) cells (Cha et al. 2012). Indeed, while it somewhat reduced tubulin protein abundance it did not elicit gross defects in the microtubule cytoskeleton (Cha et al. 2012). At angiogenesis-inhibiting doses, the overall development of TBZ treated animals is normal (Cha et al. 2012), consistent with TBZ's safety record in humans and veterinary settings (EPA 2002). We, therefore, hypothesized that specific types of human cells, such as subsets of endothelial cells involved in forming the vasculature, might be uniquely susceptible to TBZ.

Here, we used predictive molecular modeling, human cell culture, and humanized yeast, to show that TBZ predominantly targets only one of nine human β -tubulins, suggesting a possible explanation for its cell-type specificity. Moreover, based on epidemiological data mining and chemical structures, we discovered that a larger family of benzimidazoles—in clinical and commercial use for >50 years—all act as VDAs, disrupting the vasculature in a vertebrate animal model. These newly discovered VDAs include two World Health Organization (WHO) antihelmintics (albendazole and mebendazole) administered for the treatment of human intestinal infections, one broad-spectrum antifungal/antihelmintic (fenbendazole) used to treat farm animal infections, and two banned pesticides (benomyl and carbendazim) used to prevent wild fungal and nematode mediated crop destruction. Knowledge of their vascular disrupting activities should thus inform their use in at-risk individuals (such as during pregnancy) and opens new clinical applications for these compounds.

Materials and methods

Multiple sequence alignment

Human gene sequences were downloaded from the Uniprot database. The multiple sequence alignment for *Schizosaccharomyces pombe*, *Saccharomyces cerevisiae*, and 9 human β -tubulin genes was constructed using MAFFT v7 (Katoh and Standley 2013) and visualized in Geneious v10 (<https://www.geneious.com>).

Molecular modeling of β -tubulins

Homology models of human and fungal β -tubulins were constructed using as a reference structure the previously determined *Ovis aries* β -tubulin crystal structures (PDB: 3UT5 and 3N2G) (Barbier et al. 2010; Ranaivoson et al. 2012). The template was prepared using the Molecular Operating Environment (MOE.09.2014) software package from Chemical Computing Group. The structure was inspected for anomalies and protonated/charged with the Protonate3D subroutine (310 K, pH 7.4, 0.1 M salt) (Labute 2009). The protonated structure was then lightly tethered to reduce significant deviation from the empirically determined coordinates and minimized using the Amber10: EHT forcefield with R-field treatment of electrostatics to an RMS gradient of 0.1 kcal mol⁻¹ Å⁻¹. Homology models of the wild-type fungal β -tubulin were prepared by creating 25 main chain models with 25 side-chain samples at 298 K (625 total) within MOE. Intermediates were refined to an RMS gradient of 1 kcal mol⁻¹ Å⁻¹, scored with the GB/VI methodology, minimized again to an RMS gradient of 0.5 kcal mol⁻¹ Å⁻¹ and protonated. The final model for each variant was further refined by placing the protein within a 6 Å water sphere and minimizing the solvent enclosed structure to an RMS gradient of 0.001 kcal mol⁻¹ Å⁻¹. Models were evaluated by calculating Phi-Psi angles and superimposed against the reference structure. Homology models for each human β -tubulin were prepared similarly, based on generating a total of 625 models and averaging to make a final model for each β -tubulin isotype.

In silico docking of TBZ into β -tubulins

Potential binding sites were evaluated using the Site Finder application and recent computational work on benzimidazole binding to parasitic β -tubulins (Aguayo-Ortiz et al. 2013a, 2013b). Conformational variants of TBZ were created in 3-D within MOE. A database of conformations was then used to dock TBZ to the wild-type homology model using induced fit and template similarity protocols. The placement was scored with Triangle Matcher and rescored with London dG. Poses were refined with the Amber10: EHT forcefield with GVBI/WSA dG scoring. Candidate poses were then identified by inspecting polar contacts. Geometry optimization was carried out with MOPAC 7.0 using AM1. Conformational analysis of the bound structure was evaluated with LowModeMD (Labute 2010). 2-D contact maps were created using Ligand Interactions (Clark and Labute 2007).

Cell culture

HUVEC cells (tested negative for mycoplasma, bacteria, yeast, and fungi) were purchased from Clonetics and were used between passages 4 and 9. HUVECs were cultured on 0.1% gelatin-coated (Sigma) plates in endothelial growth medium-2 (EGM-2; Clonetics) in tissue culture flasks at 37°C in a humidified atmosphere of 5% CO₂. NIH-3T3 cells were obtained from Vishy Iyer at the University of Texas at Austin and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% bovine calf serum. HUVEC and NIH-3T3 cells were re-confirmed mycoplasma negative in-house; short tandem repeat profiling was not performed.

Immunohistochemistry

Cell lines were cultured in 6-well plates and treated with TBZ dissolved in 1% DMSO. Control cells received 1% DMSO. After 24 hours, cells were fixed with methanol at -20°C for 10 minutes and subsequently with 4% paraformaldehyde in PBS at room temperature for 10 minutes. Cell membranes were permeabilized with 0.2% Triton X-100 in PBS, and nonspecific antibody binding

sites were blocked with 5% goat serum for 1 hour at room temperature. Cells were incubated with primary antibodies to EB1 (BD Bioscience) and α -tubulin (Sigma) at 4°C overnight. After washing with PBST, primary antibodies were detected by Alexa Fluor-488 or 555 goat anti-rabbit or mouse immunoglobulin (IgG). 4',6-Diamidino-2-phenylindole (DAPI dye, Sigma) was added as needed to visualize nuclei.

Cell transfection and perfusion

EB3-eGFP cDNA obtained from Anna Akhmanova was cloned into the vector CS2+ (Stepanova et al. 2003). TUBB4 (Origene, RG203945) and TUBB8 (Origene, RG213889) cDNAs were purchased and cloned into the vector CS107-RFP-3Stop. HUVEC cells were transfected by nucleofection (Lonza) according to the manufacturer's instructions. To analyze the effect of TBZ in living cells, we used a closed perfusion system (POC-R2, Pecon) connected to a peristaltic pump (Ismatec). 1% DMSO, 250 μ M TBZ, or 1% DMSO diluted in EBM-2 medium was flowed at 100 μ l/min rate for the indicated times.

Western blotting

HUVECs were cultured in 6-well plates and treated with 1% DMSO or 1% DMSO, 250 μ M TBZ for 24 hours. Cells were lysed in cell lysis buffer (Cell Signaling Technology) containing 1 mM PMSF and analyzed by SDS-PAGE and western blotting using anti-EB1 (BD Bioscience) or anti-EB3 (Millipore) or anti-Clip170 (Santa Cruz) antibodies.

Imaging and image analysis

Immunohistochemistry experiments and live HUVECs were imaged using an inverted Zeiss LSM5 Pascal and Zeiss LSM700 confocal microscope, and super-resolution structured illumination (SR-SIM) combined with Zeiss LSM710 microscope. Comet lengths were measured using the software Fiji. Confocal images were cropped and enhanced in Adobe Illustrator and Adobe Photoshop for the compilation of figures.

Benzimidazole clustering analysis

Eighty-one commercially used benzimidazole compounds spanning a wide range of classes were curated from PubChem (Kim et al. 2016). JOELib (<https://sourceforge.net/projects/joelib/>), OpenBabel (O'Boyle et al. 2011), and Chem Mine features were computed using ChemMine tools (Backman et al. 2011). Heatmaps were visualized using Morpheus (<https://software.broadinstitute.org/morpheus>). Clustergrams were generated by hierarchical clustering on the one minus Pearson correlation coefficient with average linkage.

Humanizing yeast β -tubulin using CRISPR-Cas9

The human TUBB4 and TUBB8 open reading frames were integrated chromosomally (from start to stop codon) into *S. cerevisiae* in place of the endogenous TUB2 open reading frame using CRISPR/Cas9 genome editing as described previously. (Akhmetov et al. 2018). Two sgRNAs were designed targeting the yeast TUB2 locus using the Geneious (v10.2.6) CRISPR-Cas9 tools suite, purchased as oligos from IDT, and cloned into yeast CRISPR-K/O vectors using the yeast toolkit (YTK) (Lee et al. 2015) to express a synthetic guide RNA sequence, Cas9 nuclease, and a selectable marker (URA3) (Akhmetov et al. 2018; Garge et al. 2020). Repair templates were constructed by PCR amplification of the human β -tubulin ORF [from the human ORFeome (Lamesch et al. 2007)] flanked by 75 bp of target chromosomal boundary at the TUB2 locus to facilitate recombination via homology directed repair.

BY4741 (S288C) yeast strains were co-transformed with the CRISPR/Cas9 vector and repair template using Zymo Research Frozen-EZ Yeast Transformation II Kit. Transformants were selected on SC-URA media. Surviving colonies were screened by colony PCR, and Sanger sequenced to confirm replacement.

Humanized yeast growth assays

Assayed benzimidazole compounds were all dissolved in 100% DMSO to prepare stock solutions of 5 or 10 mg/ml based on solubility. Candidate VDA compounds were titrated in ranges of 5–1000 μ g/ml into growth medium depending on solubility (Supplementary Figure S6 lists specific concentrations) for subsequent growth assays. Liquid growth assays were performed in triplicate in 96-well format using a Biotek Synergy HT incubating spectrophotometer. Humanized tubulin strains were pre-cultured to saturation in YPD and diluted into 150 μ l of media to have $0.05\text{--}0.1 \times 10^7$ cells/ml. Assays were typically run for 48 hours with absorbance measured every 15 minutes.

Xenopus embryo manipulations and VDA assays

Xenopus embryos were reared in 1/3 \times Marc's modified Ringer's (MMR) solution. Each drug was treated to embryos from stage 31 until stage 38 with 10 μ g/ml or 20 μ g/ml in 1% DMSO diluted in 1/3X MMR. Embryos were fixed at stage 38 with MEMFA, and whole-mount in situ hybridization for *erg* was performed as described in Sive et al. (2000).

Data availability

All strains and reagents generated from this study are available upon request. Supplementary material is available at figshare: <https://doi.org/10.25386/genetics.14842779>.

Results

TBZ disrupts microtubule plus ends in endothelial cells

TBZ exhibits broad-spectrum activity against fungal and nematode crop pests (Lubega and Prichard 1990), but prior to our demonstration of its VDA activity (Cha et al. 2012), it was generally thought to lack activity in tetrapods (EPA 2002). Its binding target and mechanism of action remain poorly understood (Lacey and Gill 1994), but in vitro studies have suggested various benzimidazole compounds inhibit cell growth by interfering with microtubule polymerization (Davidse and Flach 1978; Lacey and Gill 1994; Aguayo-Ortiz et al. 2013b; Vela-Corcia et al. 2018). In addition, benzimidazole suppressor screens in both *S. cerevisiae* and *Caenorhabditis elegans* have independently identified resistance mutations occurring in β -tubulin genes, providing further insight (Driscoll et al. 1989; Hahnel et al. 2018). Finally, this case for a β -tubulin binding site is strengthened by numerous animal and agricultural studies also demonstrating resistance mutations arising repeatedly and independently across multiple parasitic nematode and fungal species infecting farm livestock and crops (Brown et al. 1984; Tolliver et al. 1993; Nakaune and Nakano 2007; Zhang et al. 2009; Skuce et al. 2010; Aguayo-Ortiz et al. 2013b; Carter et al. 2013; Furtado et al. 2014; Furtado and Rabelo 2015; Ramünke et al. 2016; Zhu et al. 2016; Yilmaz et al. 2017; Ali et al. 2018; Baltrušis et al. 2018; Yang et al. 2018).

Because we previously found that microtubule architecture was grossly normal in TBZ-treated HUVECs (Cha et al. 2012), we considered the possibility that TBZ may have a more subtle effect on the microtubule cytoskeleton. As an initial, simple test of this idea, we examined the localization of the plus-end binding

protein EB1 using immunostaining to detect the endogenous protein. Strikingly, we found that treatment of HUVECs with TBZ significantly reduced the accumulation of EB1 at microtubule plus ends as compared to control (Figure 1, A and B). Interestingly, when we performed the same experiment with a non-vascular cell type (NIH3T3 fibroblasts), we observed a substantially less robust effect on EB1 accumulation (Figure 1, C–E). These data raised the possibility that TBZ's interaction with may tubulin interfere with microtubule polymerization in vertebrate cells, as it does in nematodes and fungi (Dawson et al. 1984; Davidse 1986), which prompted us to explore this possibility more deeply.

TBZ selectively targets TUBB8 among human β -tubulins

Three commonly observed mutations in fungal and nematode β -tubulins (F200Y, E198A, and F167Y) confer resistance to TBZ (Figure 2, A and B), suggesting that its binding site is in the vicinity of these residues (Brown et al. 1984; Tolliver et al. 1993; Nakaune and Nakano 2007; Zhang et al. 2009; Skuce et al. 2010; Aguayo-Ortiz et al. 2013b;

Carter et al. 2013; Furtado et al. 2014; Furtado and Rabelo 2015; Ramünke et al. 2016; Zhu et al. 2016; Yilmaz et al. 2017; Ali et al. 2018; Baltrušis et al. 2018; Yang et al. 2018) (Supplementary File S1). Based on the previously observed benzimidazole suppressor mutations, we used 3D structural modeling to evaluate TBZ's potential binding sites in a fungal β -tubulin. We first constructed 3D homology models of the *S. pombe* (fission yeast) wild-type and TBZ-resistant F200Y β -tubulins, based on the previously determined *O. aries* β -tubulin crystal structures [PDB: 3UT5 (Ranaivoson et al. 2012) and 3N2G (Barbier et al. 2010)] as templates. We computationally refined the structures and then evaluated potential binding modes of TBZ, as detailed in the Methods, using computational docking algorithms to localize TBZ's potential binding sites within the fungal β -tubulin structures (Supplementary Figure S1). We identified a binding site around F200 to be the most probable (Supplementary File S2). We found that the preferred binding conformations of TBZ in both models (Supplementary Figure S1) situated close to (but distinct from) the colchicine binding site. These observations were in strong agreement with computational predictions made on parasitic β -tubulins binding




Figure 1 TBZ significantly reduces EB1 comet length at microtubule plus ends in cultured human cells. Immunohistochemical analysis of α -tubulin in two human cell lines using confocal microscopy does not show a definite distinction between 1% DMSO-treated control (A, C) and 1% DMSO, 250 μ M TBZ-treated cell lines (B, D), but images from super-resolution microscopy reveal that the accumulation of end-binding (EB) protein 1 at the plus end of microtubules is significantly reduced with TBZ treatment (B) compared to the control (A) in HUVECs. In NIH-3T3 cells, the reduced EB1 comet length following TBZ treatment (D) compared to control (C) is not as pronounced as in HUVECs, as quantified by comet length (E). Scale bars, 20 μ m in (A) and (C), 2 μ m in (A') and (C').




Figure 2 Uncovering the molecular mechanism of TBZ. (A) TBZ elicits varying activity across different clades of life being toxic to fungal and nematode clades but behaves as a VDA in tetrapods. (B) Of the 9 human β -tubulins, 8 have amino acids at positions 167, 198, and 200 that confer TBZ resistance to fungal tubulins (see Supplementary File S1), as seen in a multiple sequence alignment of human and *S. pombe* β -tubulins; only TUBB8 lacks resistance mutations. (C) *In silico* docking of TBZ (orange) into a homology modeled yeast β -tubulin 3D structure (see Materials and Methods) indicates TBZ is well-accommodated by a binding pocket in wild-type yeast NDA3 that abuts the 3 major β -tubulin TBZ resistance mutation sites. In contrast, docking of TBZ into homology models of human TUBB4 and TUBB8 indicates the potential for differential binding, with TUBB8 accommodating TBZ whereas, in the case of TUBB4, TBZ is sterically blocked. Polar contacts are illustrated via dashed lines, and residues lining the proposed binding pocket are shown in cyan. Intramolecular hydrogen bonding between E198 and Y200 in TUBB4 reorganizes the geometry of the binding pocket. Residues involved in steric clashes are depicted with a partial mesh surface. (Note that due to steric clashes between TBZ and TUBB4 at the proposed binding pocket, TBZ was superimposed from our binding model to measure interactions).

benzimidazoles (Aguayo-Ortiz *et al.* 2013b) and recent crystal structures of other benzimidazole derivatives binding to bovine brain β -tubulins (Wang *et al.* 2016).

On measuring the polar contacts and clashing energies of TBZ with tubulin, we found that the wild-type β -tubulin bound to TBZ more favorably with contact energy (-9.9 kcal/mol) as compared to its F200Y counterpart, which showed unfavorable repulsions ($+27.6$ kcal/mol) (Supplementary Files S2 and S3). For the wild-type protein, TBZ's polar contacts included E198 and Q134 (Figure 2C, Supplementary Figure S1). Arene-hydrogen interactions between the drug and protein included contributions from F200, L250, and L253. However, for our F200Y mutant, repulsion was observed in our fixed ligand experiments predominantly caused by unfavorable contacts made with Y200, F240, L250, and L253 (Supplementary Figure S1). Our analyses suggest F200Y likely forms a hydrogen bond to E198 in the TBZ-resistant mutant, thus constricting the pocket and occluding binding.

Unlike fungi, tetrapods have multiple β -tubulin isoforms (here, we use the term isotype to denote the protein products of paralogous genes, in accordance with prior tubulin literature), and their expression varies in different cells and tissue types. For example, human tubulin β I (TUBB/TUBB5) is constitutively expressed in many cells and tissues, whereas β III (TUBB3) is exclusively enriched in neurons and the brain (Kavallaris 2010; Leandro-García *et al.* 2010). The specific roles of different β -tubulin isoforms are not yet fully understood, but recent studies indicate that their sequence diversity modulates binding affinity to tubulin-binding drugs and influences microtubule dynamics through distinct interactions with molecular motors (Kavallaris 2010; Sirajuddin *et al.* 2014). The recurrence of TBZ resistance mutations at the same three loci across diverse fungi and nematodes (Supplementary File S1) led us to hypothesize that human β -tubulin isoforms might have differential sensitivities to TBZ by virtue of incorporating resistant residues at positions 167, 198, and 200, potentially explaining both its tissue-specific effects and generally low toxicity in humans.

Indeed, multiple sequence alignment of human and yeast β -tubulin genes indicated that while F167 remained conserved across all the human isoforms, positions 198 and 200 were variable (Figure 2B). Moreover, all human β -tubulin isoforms except TUBB1 and TUBB8 contain the F200Y resistance mutation. Because TUBB1 also harbors the other commonly observed E198A suppressor (Figure 2B), TUBB8 is the only human β -tubulin isotype predicted by sequence to be TBZ-sensitive. Given this variability across isoforms, we next asked how the E198A and F200Y mutations would be expected to affect TBZ's ability to bind at its predicted site in human isoforms.

We first evaluated this hypothesis computationally, by constructing 3D homology models for each of the human β -tubulin isoforms in the same manner as for the fungal model (see Materials and Methods). We then performed induced-fit docking with TBZ across our human β -tubulin models. Using a TBZ-wild-type fungal β -tubulin complex as a template, we docked TBZ into the same pocket in each of the human isoforms and measured protein-ligand interactions in the superimposed structures. In agreement with our primary sequence-based predictions, TBZ fit well into the predicted binding pocket of only TUBB1 and TUBB8, which lack the F200Y mutation. Both showed favorable binding energies of -1.8 and -8.3 kcal/mol, respectively (Supplementary File S2). The large difference in contact energy among these isoforms could be explained by position 198. In TUBB1, alanine occupies position 198, whereas TUBB8 has glutamate, which contributed heavily to the binding energy in all of our simulations when both F200 and E198 were present. Our data suggest that

TBZ binding is stabilized by hydrogen bonds with residues Q134 and E198 in the presence of F200 (Supplementary Figures S1 and S2). Taken together, our *in silico* studies predicted that TBZ should strongly bind TUBB8 and weakly bind TUBB1, but should not bind any other human β -tubulin isoforms.

Functional assays in human endothelial cells and humanized yeast confirm TBZ specificity to human TUBB8

Given TBZ's effects on human vascular endothelial cells and *in vivo* vascular disruption in *Xenopus* embryos (Cha *et al.* 2012), we wished to test directly if TUBB8-specific binding could explain the compound's effects. We thus asked whether resistance to TBZ could be acquired by simply supplying human β -tubulin isoforms predicted to be resistant. We tested this by two independent assays: (i) by overexpressing specific sensitive or resistant human β -tubulin isoforms in human endothelial cells and (ii) by humanizing Baker's yeast's β -tubulin TUB2 to enable assays of individual human β -tubulin isoforms.

To test if microtubule dynamics in human cells could be significantly restored by supplying resistant β -tubulin isoforms, we singly transfected HUVEC cells with plasmids overexpressing either TUBB4 or TUBB8 and assayed microtubule dynamics by measuring the comet lengths of end-binding protein EB3 (Figure 3A). Compared to untransfected HUVECs, we saw that overexpressing TUBB4 significantly rescued the decrease in comet length observed in TBZ-treated cells (Figure 3B). Transfection with TUBB8, by contrast, had no effect (Figure 3B). The differences became very significant after 30 minutes of exposure (Figure 3B).

As an independent assay of TBZ action on human tubulins, we turned to humanized yeast, as our previous work showed that of the nine human β -tubulins, only TUBB4 and TUBB8 could functionally replace TUB2 in *S. cerevisiae* (Garge *et al.* 2020). From our modeling and docking data, we hypothesized that yeast strains humanized with TUBB8 would be susceptible to TBZ while humanizing with TUBB4 would confer TBZ resistance. *S. cerevisiae* possesses 2 α -tubulins (TUB1 and TUB3) that interact with TUB2 to form tubulin heterodimers, which in turn oligomerize to form microtubules. Wild-type BY4741 haploid strains are TBZ-resistant. However, previous studies have shown that on deleting TUB3, yeast strains become susceptible to benzimidazoles (Schatz *et al.* 1986) likely due to reduced overall α -tubulin stoichiometry or possibly by TBZ occluding TUB2's dimerization with TUB1 but not TUB3. Therefore, we performed all our yeast replacement assays in a *tub3 Δ* background, which yielded a clear growth defect in the presence of TBZ (Supplementary Figure S3). In order to test the effect of TBZ on human β -tubulin isoforms TUBB4 and TUBB8, we used CRISPR/Cas9 to construct yeast strains with these human isoforms in place of the endogenous TUB2 and tested them in the presence or the absence of the drug (Figure 3A). We found that strains possessing wild-type TUB2 and human TUBB8 exhibited slow growth in the presence of TBZ (at conc. $20 \mu\text{g/ml}$). Particularly, we found that strains susceptible to TBZ showed a prolonged lag phase followed by a normal log phase. By contrast, the strain humanized with TUBB4, which is predicted to be resistant to TBZ, grew normally in the presence of TBZ (Figure 3C, Supplementary Figure S3A). To narrow down on the active site of TBZ, we hypothesized that mutating the 200th amino acid positions in either of the 2 replaceable β -tubulins could make them differentially resistant to TBZ. To test our modeling predictions, we humanized yeast using the Y200F allelic variant of TUBB4 and found that strains harboring this mutant




Figure 3 TBZ specifically inhibits the human β -tubulin TUBB8, not TUBB4, in humanized yeast and HUVEC cell culture. (A) Overview. TBZ's isotype specificity was identified in 2 ways. (Left) Recombinant human β -tubulins TUBB4 and TUBB8 were individually overexpressed in HUVEC cell culture to monitor comet lengths in the presence of TBZ. (Right) Using humanized yeast wherein yeast TUB2 was singly humanized by either of 2 replaceable human β -tubulins TUBB4 or TUBB8 to screen for differential sensitivity toward TBZ. (B) Reduced EB3 comet length after 1% DMSO, 250 μ M TBZ treatment compared to 1% DMSO treated control. Comet length is statistically similar between cells treated with 1% DMSO; however, following 30 minutes of 1% DMSO, 250 μ M TBZ treatment TUBB4 transfected cells have significantly longer EB3 comets than HUVECs with TUBB8 or expressing native tubulins. (C) Growth profiles of humanized yeast strains show TBZ's isotype specificity to TUBB8. When grown in the presence of TBZ, strains carrying the wild-type TUB2 (blue) and human TUBB8 (green) genes are sensitive to TBZ while humanized TUBB4 strains (orange) are resistant. Mean \pm standard deviation indicated by solid lines and shaded boundaries, respectively.

indeed became sensitive to TBZ (Supplementary Figure S4) similar to those carrying TUBB8 and wild-type TUB2.

Together with our *in silico* docking data, our results in HUVECs and humanized yeast indicate that TUBB8 is uniquely TBZ-sensitive, suggesting in turn that vascular endothelial cells are selectively sensitive to its loss.

Benzimidazole resistance patterns and chemical similarities suggest additional VDAs

Given the plethora of fungal and nematode studies on benzimidazole pesticide resistance in agriculture (Jambre et al. 1979; Middelberg and McKenna 1983; Brown et al. 1984; Dawson et al.

1984; Tolliver *et al.* 1993; Romero and Sutton 1998; Gossen *et al.* 2001; Nakaune and Nakano 2007; Saeed *et al.* 2007; Banno *et al.* 2008; Cabañas *et al.* 2009; Skuce *et al.* 2010; Niciura *et al.* 2012; Xu *et al.* 2015; Chagas *et al.* 2016; Kumar *et al.* 2016; Liu *et al.* 2016, 2018; Ramünke *et al.* 2016; Keegan *et al.* 2017; Rupp *et al.* 2017; dos Santos *et al.* 2017; Yilmaz *et al.* 2017; Ali *et al.* 2018; Yang *et al.* 2018; Zhang *et al.* 2009, Zhang *et al.*, 2016a, 2016b; Zhu *et al.* 2016) (Figure 4A), we reasoned that TBZ's molecular mechanism may extend to other commercially used benzimidazole compounds. Indeed, based on our experiments, a simple epidemiological signature should be sufficient to identify other pesticides that likely to function as VDAs and angiogenesis inhibitors: (i) the compounds should be selectively toxic to fungal and nematode clades but demonstrate low toxicity in tetrapods, and (ii) sensitive species should specifically gain benzimidazole resistance from F167Y, E198A, or F200Y β -tubulin mutations.

In order to understand how extensively distributed benzimidazole resistance was, we mined ~40 years of literature to identify reported cases of pesticide-resistant species seen in wild and parasitic nematodes and fungi. Benzimidazole resistance is a global phenomenon (Figure 4A); across 9 major commercial benzimidazole-based pesticides, we found multiple independent instances of reported resistance across 27 (12 nematodes and 15 fungal) parasitic species (Supplementary File S1), all of which exhibited at least 1 of the 3 signature β -tubulin mutations. These widespread patterns of benzimidazole pesticide resistance suggested at least 9 new candidate VDAs.

As a complement to the epidemiological data, we also considered chemical properties by asking if pesticide benzimidazoles shared similar chemical feature profiles relative to other benzimidazoles. We curated >80 commercially available compounds in the benzimidazole class spanning a diverse range including pesticides, fungicides, therapeutics, and preservatives. Upon hierarchical clustering of these benzimidazoles based on their chemical properties computed from JOELib's features matrix (Cao *et al.* 2008; Backman *et al.* 2011) (Supplementary File S5), we found that pesticide benzimidazoles generally shared similar chemical properties and clustered together (Figure 4B).

Numerous commercially used benzimidazoles also function as VDAs

We next tested if pesticides exhibiting the epidemiological signature and clustering in the same clades by virtue of their chemical features would also specifically inhibit TUBB8 and function as VDAs. We selected 12 commercially used benzimidazole compounds across 2 clusters (Figure 4B). Our list included 2 anthelmintics, both World Health Organization essential medicines (albendazole and mebendazole) prescribed to treat broad-spectrum human intestinal nematode infections; fenbendazole, an anthelmintic prescribed specifically for animals against gastrointestinal nematode parasites; 2 currently banned pesticides, benomyl, and carbendazim, formerly used in agriculture; triclabendazole, specifically used to treat liver fluke infections; and 5 proton-pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) used to treat gastrointestinal and stomach acid disorders. The latter set was from a different clade and did not exhibit the epidemiological signature, serving as negative controls.

We first took advantage of our humanized yeast strains to rapidly discriminate TUBB8-specific inhibition from general β -tubulin inhibition. We found that 5 of the 12 compounds tested selectively inhibited TUBB8, as evidenced by the growth profiles observed for the humanized strains when cultured in the

presence of the drugs (Figure 5, Supplementary Figure S5). We found that the strains did not show any growth defect in the presence of DMSO (Figure 5A). However, on growing humanized yeast strains in the presence of fenbendazole (Figure 5B), WHO human intestinal anthelmintics (Figure 5C), and broad-spectrum pesticides (Figure 5D), we found that strains with TUBB4 were largely resistant to the compounds. TUBB8 carrying humanized strains on the other hand were susceptible to the compounds similar to wild-type yeast strains. Interestingly, we found that concentrations of 20 μ g/ml the susceptible strains exhibited prolonged lag phases often failing to enter the exponential phase before 25 hours post inoculation. Notably, none of the 5 proton pump inhibitors or colchicine exhibited any tubulin inhibition (Supplementary Figures S5 and S6A), confirming the specificity of the epidemiological signature as a predictor of TUBB8 inhibition. In contrast, triclabendazole was generally toxic, behaving as a pan-isotype inhibitor (Supplementary Figure S6B).

Previously, we showed that TBZ acutely disrupted the vasculature in developing *Xenopus* embryos and in mouse xenograft assays (Cha *et al.* 2012). We, therefore, asked if the five commercially used benzimidazoles identified as inhibitors of TUBB8 also acted as VDAs in *Xenopus*. Strikingly addition of any of these compounds led to substantial disruption of the vasculature. As indicated in Figure 5A, the vasculature of early tadpole stage *Xenopus* embryos is highly patterned, with a single posterior cardinal vein running the length of the anteroposterior axis (Figure 5a, black arrow), with several nascent inter-somitic veins projecting dorsally (Figure 5A, yellow arrows). Consistent with our overall model, addition of any of the five TUBB8 inhibiting benzimidazoles was sufficient to elicit near-complete loss of intersomitic veins (ISVs) and partial disruption of posterior cardinal veins (PCV) (Figure 5). However, the gross morphology of these treated embryos was largely normal (Figure 5), as we have observed previously for TBZ (Cha *et al.* 2012). Thus, these five benzimidazoles share two effects in common: selectively inhibiting the action of TUBB8 in humanized yeast and acting as VDAs in vertebrates.

Discussion

In the >30 years of therapeutic research efforts in the angiogenesis field only a highly restricted set of drugs have yet been approved (Hinnen and Eskens 2007). Given the frequent failure to successfully make it through clinical trials and the high costs and lengthy process associated with developing new compounds, drug repurposing can offer efficient alternatives in developing new patient therapies with accelerated timeframes. This study represents a rather unconventional path to drug repurposing, leveraging a combination of model organisms, humanized yeast, cell culture, molecular modeling, and epidemiological data mining to determine TBZ's molecular target and mechanism of vascular action. Indeed, TBZ was initially identified as a VDA and angiogenesis inhibitor by using a Baker's yeast model of angiogenesis discovered in a computational search for orthologous phenotypes, or phenologs, aimed at exploiting deep evolutionary conservation to prioritize yeast processes relevant to human diseases (McGary *et al.* 2010; Cha *et al.* 2012; Woods *et al.* 2013). Although obviously lacking blood vessels and a circulatory system, yeast nonetheless retains conserved biological pathways and processes relevant to vertebrate angiogenesis genes, and it was on the basis of these conserved processes that the antifungal compound TBZ was initially suspected, later confirmed, to be an angiogenesis inhibitor (Cha *et al.* 2012).




Figure 4 Global trends in benzimidazole resistance mutations and chemical structural similarities suggest numerous potential VDAs. (A) 3 β -tubulin mutations, (F167Y, E198A, and F200Y) conferring benzimidazole resistance have been globally observed among parasitic nematode and fungal species. Each icon represents an instance of β -tubulin suppressor mutations occurring in benzimidazole resistant parasitic fungal or nematode species (see Supplementary File S1 for list of species showing benzimidazole resistance). (B) Commonly used benzimidazoles hierarchically clustered by their chemical properties suggest new VDAs with similar molecular mechanisms to TBZ. (Left) Clustergram of 81 widely used benzimidazole compounds spanning a wide range of drug classes grouped by chemical features (see Supplementary File S5 for the full list of compounds and features analyzed). (Right) Zooms of black boxes indicate 3 clades containing TUBB8 specific VDA candidates (top) and proton-pump inhibitors (bottom).

While TBZ somewhat reduced the abundance of tubulin proteins in human cells (Cha et al. 2012), at angiogenesis-inhibiting doses, the overall morphology of TBZ treated animals was normal, suggesting that only certain cell types, specifically those endothelial cells involved in forming the vasculature, might be uniquely susceptible to TBZ. Here, we find that TBZ does indeed specifically modulate the microtubules in vascular endothelial cells. Several currently identified microtubule targeting drugs

have been reported to interfere with polymerization dynamics by binding β -tubulin (Hinnen and Eskens 2007; Tozer et al. 2005) close to or at the colchicine binding site. Building on previous work (Aguayo-Ortiz et al. 2013b; Wang et al. 2016), our *in silico* modeling results suggest that TBZ's binding site, while in close proximity to the colchicine binding site, is distinct from it, thereby uncovering a novel β -tubulin effector site likely specific to other benzimidazoles and TBZ analogs.




Figure 5 Commercially used benzimidazole pesticides, antifungals, and antihelminthics are also TUBB8-specific and disrupt vasculature. (A–D) *In situ* hybridization of blood vessels [using the *erg/flk1* probe (McGary et al. 2010)] in *Xenopus laevis* embryos indicate the disruption of the vasculature in the intersomitic (ISV, yellow arrows) and posterior cardinal veins (PCV, black arrows) caused by the presence of human and animal antihelminthics and broad-spectrum pesticides as compared to the DMSO control. Insets show growth profiles for yeast strains with humanized β -tubulin TUBB4 (orange) and TUBB8 (green) compared to wild-type (blue) when grown in the presence of each compound. Mean \pm standard deviation indicated by solid lines and shaded boundaries, respectively.

In contrast to β -tubulin anticancer drugs, which have largely shown pan-isotype activity, to our knowledge, this study presents an unusual case of isotype-specific drug targeting in the β -tubulin gene family. Fungal suppressor studies on benzimidazole resistance have repeatedly found resistant mutations in β -tubulin; we found that 8 of 9 human β -tubulins natively harbor the same suppressor mutations and consequently exhibit unfavorable steric clashes interfering with TBZ binding. We demonstrate both via human cell culture microtubule assays and humanized yeast drug sensitivity tests that TBZ selectively targets only TUBB8 among the nine human β -tubulins, thus disrupting microtubule dynamics and reducing end-binding protein accumulation at the plus ends of microtubules in susceptible cells. An interesting

observation to note is that TBZ susceptible strains (at lower TBZ concentrations) exhibited prolonged lag phases before returning to log phases comparable to those of the TUBB4 humanized strains. These humanized strains were used as tools to screen TBZ's specificity. However, understanding how TBZ impacts specific β -tubulin isotypes would shed light on aspects of microtubule and cytoskeletal biology often hard to study in human cells.

With TUBB8 thus acting as the specific target, it follows that of all human cell types, vascular endothelial cells must in turn be particularly sensitive to inhibition of TUBB8, leading to selective disruption of the vasculature relative to other human tissues. It remains to be seen why TBZ's vascular disrupting activity is restricted to immature or newly forming blood vessels, but we

speculate that this subset of the vasculature lacks reinforcing cell-cell contacts typical of larger, more established vasculature, leading to greater sensitivity to TBZ-induced microtubule disruption. Analyzing protein abundances from a recent HUVEC proteome study (Madugundu et al. 2019), we found that TUBB8 is among the top 50 most abundant proteins (Supplementary Figure S7). However, β -tubulin isoforms tend to be broadly expressed and often substitute for one another in microtubule structures (The UniProt Consortium, 2019; Uhlén et al. 2015). One possibility is that TUBB8 inhibition simply leads to the loss of vasculature-specific microtubule roles and its interactions with endothelial cell-specific components, thus specifically impacting vasculogenesis/angiogenesis. However, gene-gene and gene-drug interactions can often proceed by less obviously direct mechanisms to selectively impact cell types or phenotype penetrance via conditional cell-specific or dosage-dependent synthetic interactions (Burga et al. 2011; O'Neil et al. 2017). It would thus not be surprising for the consequences of inhibiting TUBB8 in vascular endothelial cells to be similarly indirectly mediated by endothelial cell-specific synthetic interactions. Further experiments characterizing TBZ's selective activity against newly forming/formed vasculature and the vascular-specific roles of TUBB8 in tetrapods could offer valuable insights into the cytoskeletal dynamics underlying vasculogenesis and angiogenesis.

Based on chemical properties and signature resistance mutations observed against benzimidazole compounds, we identified a larger class of extensively used fungicides and pesticides that all exhibit vascular disruption activity. While our results suggest possible new clinical applications for these compounds, they also highlight the potential caveats of their use in at-risk populations, especially for the two compounds (albendazole and mebendazole) that are FDA approved for human use. The WHO recommends the use of both albendazole and mebendazole as essential anti-helmenthics worldwide for children up to the age of 14 against soil-transmitted helminth infections. Moreover, these compounds are widely used as public health interventions in pregnant women after the first trimester in regions where hookworm and whipworm infections exceed 20% (World Health Organization 2018). While in the US, the risk of mebendazole use during pregnancy has not been assigned, our data add weight to WHO recommendations that these drugs should not be administered in the first trimester of pregnancy and suggest their use be carefully evaluated in patients in which angiogenesis inhibition might pose risks, including using caution later in pregnancy in light of the evidence that the compounds disrupt immature vasculature and might prove harmful to a developing fetus. Conversely, while efforts in the angiogenesis field have been often motivated toward developing anticancer therapies, the wide use of the compounds discussed here and their FDA-approved status could open alternative paths to treating other angiogenesis and/or vascular-related diseases, such as diabetic retinopathy, macular degeneration, and hemangioma. It remains to be seen if other benzimidazoles sharing similar chemical profiles to those tested in our work (such as ciclo bendazole, nocodazole, oxibendazole, and oxfendazole) also exhibit vascular disrupting activity.

More broadly, our framework of leveraging phenotypic relationships between species and repurposing model organisms to systematically explore drug mechanisms opens new routes for drug repurposing and discovery, and highlights the power of systems biology and evolution-guided approaches in advancing our knowledge of conserved genetic modules and how their disruption manifests in disease. This work also illustrates how duplicated genes diversify their functions and reinforces the

therapeutic benefits of finding drugs specific to individual gene family members. As evidenced by the high degree of replaceability of conserved genes from cross-species complementation assays (Kachroo et al. 2015; Laurent et al. 2016, 2020), we anticipate that the combination of humanized yeast and phenology-based disease modeling can be extended beyond vascular disruption to other conserved processes and therapies targeting them.

Acknowledgments

The authors gratefully thank Andrew Ellington for critical feedback and discussions and Justin Lau and Chris Sullivan for performing mycoplasma tests. Conceptualization and methodology, R.K.G., H.J.C., J.D.G., A.H.K., J.B.W., and E.M.M.; Computational analyses, R.K.G., H.J.C., and J.D.G.; Investigation, R.K.G., H.J.C., C.L., and J.D.G.; Formal analysis and visualization, R.K.G., H.J.C., and E.M.M.; Writing, R.K.G., H.J.C., J.B.W., and E.M.M.

Funding

This research was funded by the American Heart Association Predoctoral fellowship (#18PRE34060258) to R.K.G., Army Research Office (W911NF-12-1-0390) to J.D.G., Natural Sciences and Engineering Research Council (NSERC) of Canada Discovery grant (RGPIN-2018-05089), CRC Tier 2 (NSERC/CRSNG-950-231904), and the Canada Foundation for Innovation and Québec Ministère de l'Économie, de la Science et de l'Innovation (#37415) to A.H.K., the National Institute of Child Health and Human Development (R01HD099191) to J.B.W., and from the Welch Foundation (F-1515) and National Institutes of Health (R35 GM122480) to E.M.M.

Conflicts of interest

None declared.

Literature cited

- Aguayo-Ortiz R, Méndez-Lucio O, Castillo R, Yépez-Mulia L, Medina-Franco JL, et al. 2013a. Molecular basis for benzimidazole resistance from a novel β -tubulin binding site model. *J Mol Graph Model*. doi:10.1016/j.jmglm.2013.07.008.
- Aguayo-Ortiz R, Méndez-Lucio O, Medina-Franco JL, Castillo R, Yépez-Mulia L, et al. 2013b. Towards the identification of the binding site of benzimidazoles to β -tubulin of *Trichinella spiralis*: insights from computational and experimental data. *J Mol Graph Model*. 41:12–19. doi:10.1016/j.jmglm.2013.01.007.
- Akhmetov A, Laurent J, Gollihar J, Gardner E, Garge R, et al. 2018. Single-step precision genome editing in yeast using CRISPR-Cas9. *Bio Protoc*. 8:e2765. doi:10.21769/BioProtoc.2765.
- Ali Q, Rashid I, Shabbir MZ, Rahman A-U, Shahzad K, et al. 2018. Emergence and the spread of the F200Y benzimidazole resistance mutation in *Haemonchus contortus* and *Haemonchus placei* from buffalo and cattle. *bioRxiv*. 425660: doi:10.1101/425660.
- Backman TWH, Cao Y, Girke T. 2011. ChemMine tools: an online service for analyzing and clustering small molecules. *Nucleic Acids Res*. 39:W486–W491. doi:10.1093/nar/gkr320.
- Baltrušis P, Halvarsson P, Höglund J. 2018. Exploring benzimidazole resistance in *Haemonchus contortus* by next generation sequencing and droplet digital PCR. *Int J Parasitol Drugs Drug Resist*. 8: 411–419. doi:10.1016/j.ijpddr.2018.09.003.

- Banno S, Fukumori F, Ichiishi A, Okada K, Uekusa H, et al. 2008. Genotyping of Benzimidazole-resistant and dicarboximide-resistant mutations in *Botrytis cinerea* using real-time polymerase chain reaction assays. *Phytopathology*. 98:397–404. doi:10.1094/PHYTO-98-4-0397.
- Barbier P, Dorléans A, Devred F, Sanz L, Allegro D, et al. 2010. Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers. *J Biol Chem*. 285:31672–31681. doi:10.1074/jbc.M110.141929.
- Brown MC, Taylor GS, Epton HAS. 1984. Carbendazim resistance in the eyespot pathogen *Pseudocercospora herpotrichoides*. *Plant Pathol*. 33:101–111. doi:10.1111/j.1365-3059.1984.tb00593.x.
- Burga A, Casanueva MO, Lehner B. 2011. Predicting mutation outcome from early stochastic variation in genetic interaction partners. *Nature*. 480:250–253. doi:10.1038/nature10665.
- Cabañas R, Castellá G, Abarca ML, Bragulat MR, Cabañes FJ. 2009. Thiabendazole resistance and mutations in the β -tubulin gene of *Penicillium expansum* strains isolated from apples and pears with blue mold decay. *FEMS Microbiol Lett*. 297:189–195. doi:10.1111/j.1574-6968.2009.01670.x.
- Cai SX. 2007. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. *Recent Pat Anticancer Drug Discov*. 2:79–101. doi:10.2174/157489207779561462.
- Cao Y, Charisi A, Cheng L-C, Jiang T, Girke T. 2008. Chemminer: A compound mining framework for R. *Bioinformatics*. 24:1733–1734. doi:10.1093/bioinformatics/btn307.
- Carmeliet P. 2005. Angiogenesis in life, disease and medicine. *Nature*. 438:932–936. doi:10.1038/nature04478.
- Carter HE, Cools HJ, West JS, Shaw MW, Fraaije BA. 2013. Detection and molecular characterisation of Pyrenopeziza brassicae isolates resistant to methyl benzimidazole carbamates. *Pest Manag Sci*. 69:1040–1048. doi:10.1002/ps.3585.
- Cha HJ, Byrom M, Mead PE, Ellington AD, Wallingford JB, et al. 2012. Evolutionarily repurposed networks reveal the well-known anti-fungal drug thiabendazole to be a novel vascular disrupting agent. *PLoS Biol*. 10:e1001379. doi:10.1371/journal.pbio.1001379.
- Chagas AM, Sampaio Junior FD, Pacheco A, da Cunha AB, Cruz J. D S, et al. 2016. F200Y polymorphism of the β -tubulin isotype 1 gene in *Haemonchus contortus* and sheep flock management practices related to anthelmintic resistance in eastern Amazon. *Vet Parasitol*. 226:104–108. doi:10.1016/j.vetpar.2016.06.038.
- Clark AM, Labute P. 2007. 2D depiction of protein–ligand complexes. *J Chem Inf Model*. 47:1933–1944. doi:10.1021/ci7001473.
- Davidse LC. 1986. Benzimidazole fungicides: mechanism of action and biological impact. *Annu Rev Phytopathol*. 24:43–65. doi:10.1146/annurev.py.24.090186.000355.
- Davidse LC, Flach W. 1978. Interaction of thiabendazole with fungal tubulin. *Biochim Biophys Acta*. 543:82–90. doi:10.1016/0304-4165(78)90456-7.
- Dawson PJ, Gutteridge WE, Gull K. 1984. A comparison of the interaction of anthelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode *Ascaridia galli*. *Biochem Pharmacol*. 33:1069–1074. doi:10.1016/0006-2952(84)90515-X.
- dos Santos JML, Vasconcelos JF, Frota GA, Ribeiro WLC, André WPP, et al. 2017. *Haemonchus contortus* β -tubulin isotype 1 gene F200Y and F167Y SNPs are both selected by ivermectin and oxfendazole treatments with differing impacts on anthelmintic resistance. *Vet Parasitol*. 248:90–95. doi:10.1016/j.vetpar.2017.11.003.
- Driscoll M, Dean E, Reilly E, Bergholz E, Chalfie M. 1989. Genetic and molecular analysis of a *Caenorhabditis elegans* beta-tubulin that conveys benzimidazole sensitivity. *J Cell Biol*. 109:2993–3003.
- El-Kenawi AE, El-Remessy AB. 2013. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. *Br J Pharmacol*. 170:712–729. doi:10.1111/bph.12344.
- EPA 2002. Thiabendazole and salts R.E.D Factsheet. United States Environmental Protection Agency. https://archive.epa.gov/pesticides/reregistration/web/pdf/thiabendazole_red.pdf
- Folkman J. 2007. Opinion: angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov*. 6:273–286. doi:10.1038/nrd2115.
- Folkman J. 2004. Endogenous angiogenesis inhibitors. *Acta Pharmacol Sin*. 112:496–507. doi:10.1111/j.1600-0463.2004.apm11207-0809.x.
- Furtado LFV, Bello ACPDP, dos Santos HA, Carvalho MRS, Rabelo ÉML. 2014. First identification of the F200Y SNP in the β -tubulin gene linked to benzimidazole resistance in *Ancylostoma caninum*. *Vet Parasitol*. 206:313–316. doi:10.1016/j.vetpar.2014.10.021.
- Furtado LFV, Rabelo ÉML. 2015. Molecular analysis of the F167Y SNP in the β -tubulin gene by screening genotypes of two *Ancylostoma caninum* populations. *Vet Parasitol*. 210:114–117. doi:10.1016/j.vetpar.2015.03.018.
- Garge RK, Laurent JM, Kachroo AH, Marcotte EM. 2020. Systematic humanization of the yeast cytoskeleton discerns functionally replaceable from divergent human genes. *Genetics*. 215:1153–1169. doi:10.1534/genetics.120.303378.
- Gossen BD, Rimmer SR, Holley JD. 2001. First report of resistance to benomyl fungicide in *Sclerotinia sclerotiorum*. *Plant Disease*. 85:1206. doi:10.1094/PDIS.2001.85.11.1206C.
- Hahnel SR, Zdraljevic S, Rodriguez BC, Zhao Y, McGrath PT, et al. 2018. Extreme allelic heterogeneity at a *Caenorhabditis elegans* beta-tubulin locus explains natural resistance to benzimidazoles. *PLoS Pathog*. 14:e1007226. doi:10.1371/journal.ppat.1007226.
- Heath VL, Bicknell R. 2009. Anticancer strategies involving the vasculature. *Nat Rev Clin Oncol*. 6:395–404. doi:10.1038/nrclinonc.2009.52.
- Herbert SP, Stainier DYR. 2011. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. *Nat Rev Mol Cell Biol*. 12:551–564. doi:10.1038/nrm3176.
- Hinnen P, Eskens FALM. 2007. Vascular disrupting agents in clinical development. *Br J Cancer*. 96:1159–1165. doi:10.1038/sj.bjc.6603694.
- Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, et al. 2013. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate. *BMC Pharmacol Toxicol*. 14:7. doi:10.1186/2050-6511-14-7.
- Jambre LFL, Martin PJ, Webb RF. 1979. Thiabendazole resistance in field populations of *Haemonchus contortus*. *Aust Vet J*. 55:163–166. doi:10.1111/j.1751-0813.1979.tb15263.x.
- Kachroo AH, Laurent JM, Yellman CM, Meyer AG, Wilke CO, et al. 2015. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. *Science*. 348:921–925. doi:10.1126/science.aaa0769.
- Katoh K, Standley DM. 2013. MAFFT Multiple Sequence Alignment Software Version 7: improvements in performance and usability. *Mol Biol Evol*. 30:772–780. doi:10.1093/molbev/mst010.
- Kavallaris M. 2010. Microtubules and resistance to tubulin-binding agents. *Nat Rev Cancer*. 10:194–204. doi:10.1038/nrc2803.
- Keegan JD, Good B, de Waal T, Fanning J, Keane OM. 2017. Genetic basis of benzimidazole resistance in *Teladorsagia circumcincta* in Ireland. *Ir Vet J*. 70:8. doi:10.1186/s13620-017-0087-8.
- Kerbel RS. 2008. Tumor angiogenesis. *N Engl J Med*. 358:2039–2049. doi:10.1056/NEJMr0706596.
- Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, et al. 2016. PubChem substance and compound databases. *Nucleic Acids Res*. 44:D1202–D1213. doi:10.1093/nar/gkv951.

- Kumar S, Garg R, Kumar S, Banerjee PS, Ram H, et al. 2016. Benzimidazole resistance in equine cyathostomins in India. *Vet Parasitol.* 218:93–97. doi:10.1016/j.vetpar.2016.01.016.
- Labute P. 2010. LowModeMD—implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops. *J Chem Inf Model.* 50:792–800. doi:10.1021/ci900508k.
- Labute P. 2009. Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. *Proteins.* 75:187–205. doi:10.1002/prot.22234.
- Lacey E, Gill JH. 1994. Biochemistry of benzimidazole resistance. *Acta Trop.* 56:245–262. doi:10.1016/0001-706X(94)90066-3.
- Lamesch P, Li N, Milstein S, Fan C, Hao T, et al. 2007. hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. *Genomics.* 89:307–315. doi:10.1016/j.ygeno.2006.11.012.
- Laurent JM, Garge RK, Teufel AI, Wilke CO, Kachroo AH, et al. 2020. Humanization of yeast genes with multiple human orthologs reveals functional divergence between paralogs. *PLoS Biol.* 18:e3000627. doi:10.1371/journal.pbio.3000627.
- Laurent JM, Young JH, Kachroo AH, Marcotte EM. 2016. Efforts to make and apply humanized yeast. *Brief Funct Genomics.* 15:155–163. doi:10.1093/bfpg/elfv041.
- Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, et al. 2010. Tumoral and tissue-specific expression of the major human beta-tubulin isoforms. *Cytoskeleton (Hoboken).* 67:214–223. doi:10.1002/cm.20436.
- Lee ME, DeLoache WC, Cervantes B, Dueber JE. 2015. A highly characterized yeast toolkit for modular, multipart assembly. *ACS Synth Biol.* 4:975–986. doi:10.1021/sb500366v.
- Lippert JW. 2007. Vascular disrupting agents. *Bioorg Med Chem.* 15:605–615. doi:10.1016/j.bmc.2006.10.020.
- Liu S, Che Z, Chen G. 2016. Multiple-fungicide resistance to carbendazim, diethofencarb, procymidone, and pyrimethanil in field isolates of *Botrytis cinerea* from tomato in Henan Province. *China Crop Protection.* 84:56–61. doi:10.1016/j.cropro.2016.02.012.
- Liu S, Zhang Y, Jiang J, Che Z, Tian Y, et al. 2018. Carbendazim resistance and dimethachlone sensitivity of field isolates of *Sclerotinia sclerotiorum* from oilseed rape in Henan Province. *J Phytopathol.* 166:701–708. doi:10.1111/jph.12751.
- Lubega GW, Prichard RK. 1990. Specific interaction of benzimidazole anthelmintics with tubulin: high-affinity binding and benzimidazole resistance in *Haemonchus contortus*. *Mol Biochem Parasitol.* 38:221–232. doi:10.1016/0166-6851(90)90025-H.
- Madugundu AK, Na CH, Nirujogi RS, Renuse S, Kim KP, et al. 2019. Integrated transcriptomic and proteomic analysis of primary human umbilical vein endothelial cells. *Proteomics.* 19:1800315. doi:10.1002/pmic.20.
- Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG. 2011. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. *Integr Biol (Camb).* 3:375–387. doi:10.1039/c0ib00135j.
- McGary KL, Park TJ, Woods JO, Cha HJ, Wallingford JB, et al. 2010. Systematic discovery of nonobvious human disease models through orthologous phenotypes. *Proc Natl Acad Sci USA.* 107:6544–6549. doi:10.1073/pnas.0910200107.
- Middelberg A, McKenna PB. 1983. Oxfendazole resistance in *Nematodirus spathiger*. *N Z Vet J.* 31:65–66. doi:10.1080/00480169.1983.34971.
- Nakaune R, Nakano M. 2007. Benomyl resistance of *Colletotrichum acutatum* is caused by enhanced expression of β -tubulin 1 gene regulated by putative leucine zipper protein CaBEN1. *Fungal Genet Biol.* 44:1324–1335. doi:10.1016/j.fgb.2007.03.007.
- Niciura SCM, Verissimo CJ, Gromboni JGG, Rocha MIP, de Mello SS, et al. 2012. F200Y polymorphism in the β -tubulin gene in field isolates of *Haemonchus contortus* and risk factors of sheep flock management practices related to anthelmintic resistance. *Vet Parasitol.* 190:608–612. doi:10.1016/j.vetpar.2012.07.016.
- Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AHC. 2013. Photodynamic therapy for polypoidal choroidal vasculopathy. *Prog Retin Eye Res.* 37:182–199. doi:10.1016/j.preteyeres.2013.09.003.
- Nyberg P, Xie L, Kalluri R. 2005. Endogenous inhibitors of angiogenesis. *Cancer Res.* 65:3967–3979. doi:10.1158/0008-5472.CAN-04-2427.
- O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. 2011. Open babel: an open chemical toolbox. *J Cheminform.* 3:33. doi:10.1186/1758-2946-3-33.
- O'Neil NJ, Bailey ML, Hieter P. 2017. Synthetic lethality and cancer. *Nat Rev Genet.* 18:613–623. doi:10.1038/nrg.2017.47.
- O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell.* 88:277–285. doi:10.1016/s0092-8674(00)81848-6.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. *Cell.* 79:315–328. doi:10.1016/0092-8674(94)90200-3.
- Ramünke S, Melville L, Rinaldi L, Hertzberg H, de Waal T, et al. 2016. Benzimidazole resistance survey for *Haemonchus*, *Teladorsagia* and *Trichostrongylus* in three European countries using pyrosequencing including the development of new assays for *Trichostrongylus*. *Int J Parasitol Drugs Drug Resist.* 6:230–240. doi:10.1016/j.ijpddr.2016.10.002.
- Ranaivoson FM, Gigant B, Bertré S, Joullie M, Knossow M. 2012. Structural plasticity of tubulin assembly probed by vinca-domain ligands. *Acta Crystallogr D Biol Crystallogr.* 68:927–934. doi:10.1107/S0907444912017143.
- Romero RA, Sutton TB. 1998. Characterization of benomyl resistance in *Mycosphaerella fijiensis*, cause of black sigatoka of Banana, in Costa Rica. *Plant Dis.* 82:931–934. doi:10.1094/PDIS.1998.82.8.931.
- Rupp S, Plesken C, Rumsey S, Dowling M, Schnabel G, et al. 2017. *Botrytis fragariae*, a new species causing gray mold on strawberries, shows high frequencies of specific and efflux-based fungicide resistance. *Appl Environ Microbiol.* 83:9. doi:10.1128/AEM.00269-17.
- Saeed M, Iqbal Z, Jabbar A. 2007. Oxfendazole resistance in gastrointestinal nematodes of beetal goats at livestock farms of Punjab (Pakistan). *Acta Vet Brno.* 76:79–85. doi:10.2754/avb200776010079.
- Schatz PJ, Solomon F, Botstein D. 1986. Genetically essential and non-essential alpha-tubulin genes specify functionally interchangeable proteins. *Mol Cell Biol.* 6:3722–3733. doi:10.1128/MCB.6.11.3722.
- Sirajuddin M, Rice LM, Vale RD. 2014. Regulation of microtubule motors by tubulin isoforms and post-translational modifications. *Nat Cell Biol.* 16:335–344. doi:10.1038/ncb2920.
- Sive HL, Grainger RM, Harland RM. Early Development of *Xenopus Laevis*: A Laboratory Manual. Cold Spring Harbor Laboratory Press 2000.
- Skuce P, Stenhouse L, Jackson F, Hypša V, Gilleard J. 2010. Benzimidazole resistance allele haplotype diversity in United Kingdom isolates of *Teladorsagia circumcincta* supports a hypothesis of multiple origins of resistance by recurrent mutation. *Int J Parasitol.* 40:1247–1255. doi:10.1016/j.ijpara.2010.03.016.
- Stepanova T, Slemmer J, Hoogenraad CC, Lansbergen G, Dortland B, et al. 2003. Visualization of microtubule growth in cultured neurons via the Use of EB3-GFP (End-Binding Protein 3-Green Fluorescent Protein). *J Neurosci.* 23:2655–2664. doi:10.1523/JNEUROSCI.23-07-02655.2003.

- Taylor RD, MacCoss M, Lawson ADG. 2014. Rings in drugs: miniper-spective. *J Med Chem.* 57:5845–5859. doi:10.1021/jm4017625.
- The UniProt Consortium 2019. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* 47:D506–D515. doi:10.1093/nar/gky1049.
- Tolliver SC, Lyons ET, Drudge JH, Stamper S, Granstrom DE. 1993. Critical tests of thiabendazole, oxiabendazole, and oxfendazole for drug resistance of population-B equine small strongyles (1989 and 1990). *Am J Vet Res.* 54:908–913.
- Tozer GM, Kanthou C, Baguley BC. 2005. Disrupting tumour blood vessels. *Nat Rev Cancer.* 5:423–435. doi:10.1038/nrc1628.
- Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, et al. 2015. Tissue-based map of the human proteome. *Science.* 347:1260419. doi:10.1126/science.1260419.
- Vela-Corcía D, Romero D, A de V, Pérez-García A. 2018. Analysis of β -tubulin-carbendazim interaction reveals that binding site for MBC fungicides does not include residues involved in fungicide resistance. *Sci Rep.* 8:7161. doi:10.1038/s41598-018-25336-5.
- Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, et al. 2016. Structures of a di-verse set of colchicine binding site inhibitors in complex with tu-bulin provide a rationale for drug discovery. *Febs J.* 283:102–111. doi:10.1111/febs.13555.
- Woods JO, Singh-Blom UM, Laurent JM, McGary KL, Marcotte EM. 2013. Prediction of gene-phenotype associations in humans, mice, and plants using phenologs. *BMC Bioinformatics.* 14:203. doi:10.1186/1471-2105-14-203.
- World Health Organization. 2018. Preventive chemotherapy to con-trol soil-transmitted helminth infections in at-risk population groups. S.l.: World Health Organization.
- Xu D, Pan Y, Zhang H, Li X, Dai Y, et al. 2015. Detection and character-ization of carbendazim resistance in *Sclerotinia sclerotiorum* iso-lates from oilseed rape in Anhui Province of China. *Genet Mol Res.* 14:16627–16638. doi:10.4238/2015.December.11.10.
- Yang Y, Li M-X, Duan Y-B, Li T, Shi Y-Y, et al. 2018. A new point muta-tion in β 2-tubulin confers resistance to carbendazim in *Fusarium asiaticum*. *Pestic Biochem Physiol.* 145:15–21. doi:10.1016/j.pestbp.2017.12.006.
- Yilmaz E, Ramünke S, Demeler J, Krücken J. 2017. Comparison of constitutive and thiabendazole-induced expression of five cyto-chrome P450 genes in fourth-stage larvae of *Haemonchus contortus* isolates with different drug susceptibility identifies one gene with high constitutive expression in a multi-resistant isolate. *Int J Parasitol Drugs Drug Resist.* 7:362–369. doi:10.1016/j.ijpddr.2017.10.001.
- Zhang H, Brankovics B, van der LT, Waalwijk C, van DA, et al. 2016a. A single-nucleotide-polymorphism-based genotyping assay for simultaneous detection of different carbendazim-resistant ge-notypes in the *Fusarium graminearum* species complex. *PeerJ.* 4:e2609. doi:10.7717/peerj.2609.
- Zhang Y-J, Yu J-J, Zhang Y-N, Zhang X, Cheng C-J, et al. 2009. Effect of carbendazim resistance on trichothecene production and aggres-siveness of *Fusarium graminearum*. *Mol Plant Microbe Interact.* 22:1143–1150. doi:10.1094/MPMI-22-9-1143.
- Zhang Z, Gasser RB, Yang X, Yin F, Zhao G, et al. 2016b. Two benz-imidazole resistance-associated SNPs in the isotype-1 β -tubulin gene predominate in *Haemonchus contortus* populations from eight regions in China. *International Journal for Parasitology: Drugs and Drug Resistance*, Includes articles from the scientific meeting: “Anthelmintics: From Discovery to Resistance II,” pp. 288–370. 6:199–206. doi:10.1016/j.ijpddr.2016.10.001.
- Zhu Z-Q, Zhou F, Li J-L, Zhu F-X, Ma H-J. 2016. Carbendazim resis-tance in field isolates of *Sclerotinia sclerotiorum* in China and its management. *Crop Protection.* 81:115–121. doi:10.1016/j.cro-pro.2015.12.011.

Communicating editor: A. Gladfelter